Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator

Accelerating global antibacterial innovation Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership accelerating antibacterial products to address drug-resistant bacteria, a leading cause of death around the world. The CARB-X portfolio is the world’s most scientifically diverse, early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products. CARB-X is the only global partnership that integrates solutions for the prevention, diagnosis and treatment of life-threatening bacterial infections, translating innovation from basic research to first-in-human clinical trials. CARB-X is funded by a global consortium of governments and foundations. CARB-X headquarters are located at Boston University. Our vision Life-saving innovation to keep the world prepared for dangerous bacterial infections. Our mission Accelerate a diverse portfolio of innovative antibacterial products towards clinical development and regulatory approval with funding, expert support and portfolio acceleration tools. We focus on the dangerous bacteria identified by the WHO and CDC priority lists.